Cargando…

Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19

OBJECTIVES: Intracerebral hemorrhage/bleeding (ICH) after an infection with SARS-CoV-2 (COVID-19) treated with the Janus-kinase inhibitor baricitinib has not been reported. CASE PRESENTATION: A 86yo Caucasian female suddenly developed aphasia with a systolic blood pressure of 220 mmHg. Cerebral imag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Finsterer, Josef, Scorza, Fulvio A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256660/ https://www.ncbi.nlm.nih.gov/pubmed/34250455 http://dx.doi.org/10.1016/j.hest.2021.06.005

Ejemplares similares

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
por: Praveen, D., et al.
Publicado: (2020)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
por: Kubo, Satoshi, et al.
Publicado: (2018)

DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
por: Sonia, Chiging, et al.
Publicado: (2022)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
por: Mayence, Annie, et al.
Publicado: (2019)

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2019)

Mediastinal and pleural lipomatosis as a manifestation of myotonic dystrophy type 1
por: Finsterer, Josef, et al.
Publicado: (2021)

Atomoxetine-induced focal seizures with contralateral hypoperfusion and hyper-CKemia
por: Finsterer, Josef, et al.
Publicado: (2020)

Apparent onset of COVID-19 after onset of SARS-CoV-2 associated Guillain-Barre syndrome
por: Scorza, Fulvio A., et al.
Publicado: (2021)

Outcome of Endovascular-Treated Subarachnoid Bleeding Triggering Pulmonary and Cardiac Takotsubo
por: Finsterer, Josef, et al.
Publicado: (2020)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
por: Thudium, Christian S., et al.
Publicado: (2020)

Guillain-Barre syndrome in 220 patients with COVID-19
por: Finsterer, Josef, et al.
Publicado: (2021)

Guillain-Barré Syndrome Associated with COVID-19 Vaccination
por: Finsterer, Josef, et al.
Publicado: (2022)

Comparing Neuro-COVID-19 between Waves Requires Clear Cohort Selection
por: Finsterer, Josef, et al.
Publicado: (2023)

Infectious and immune-mediated central nervous system disease in 48 COVID-19 patients
por: Finsterer, Josef, et al.
Publicado: (2021)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Consider alternative causes of thrombo-embolism to SARS-CoV-2 in COVID-19 patients
por: Finsterer, Josef, et al.
Publicado: (2022)

Abnormal cerebrospinal fluid composition can accompany central nervous system involvement in COVID-19
por: Finsterer, Josef, et al.
Publicado: (2022)

Adherence to Clear-cut Definitions Is Mandatory When Assessing Short- and Long-term Neurological Complications of COVID-19
por: Finsterer, Josef, et al.
Publicado: (2022)

The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes
por: Joyo, Yuji, et al.
Publicado: (2022)

Extrapulmonary onset manifestations of COVID-19
por: Finsterer, Josef, et al.
Publicado: (2021)

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera
por: Wei, Jenny J., et al.
Publicado: (2019)

Ischemic stroke in 455 COVID-19 patients
por: Finsterer, Josef, et al.
Publicado: (2022)

Perspectives of Neuro-COVID: Myasthenia
por: Finsterer, Josef, et al.
Publicado: (2021)

Clinical and Pathophysiologic Spectrum of Neuro-COVID
por: Finsterer, Josef, et al.
Publicado: (2021)

Neuro-COVID Requires Comprehensive Work-up
por: Finsterer, Josef, et al.
Publicado: (2021)

Establishing causality between SARS-CoV-2 and stroke/bleeding requires a temporal relationship and plausible pathophysiology
por: Finsterer, Josef, et al.
Publicado: (2022)

Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
por: Akbarzadeh-Khiavi, Mostafa, et al.
Publicado: (2021)

Investigation on the binding behavior of human α1-acid glycoprotein with Janus Kinase inhibitor baricitinib: Multi-spectroscopic and molecular simulation methodologies
por: Jiang, Shao-Liang, et al.
Publicado: (2023)

Consider differentials before diagnosing COVID-19 associated polyradiculitis
por: Finsterer, Josef, et al.
Publicado: (2022)

Dystonia as a complication of COVID-19 vaccinations is not as rare as portrayed
por: Scorza, Fulvio Alexandre, et al.
Publicado: (2022)

Presentation and pathophysiology of neuro-COVID
por: Finsterer, Josef, et al.
Publicado: (2021)

Is insulin resistance truly responsible for post-COVID depression?
por: Finsterer, Josef, et al.
Publicado: (2023)

Letter to the Editor: Ischemic Stroke of the Corpus Callosum after SARS-CoV-2 Vaccination
por: Finsterer, Josef, et al.
Publicado: (2021)

Exclude differentials before attributing post-COVID fatigue to myopathy
por: Finsterer, Josef, et al.
Publicado: (2021)

COVID-19 associated cranial nerve neuropathy: A systematic review
por: Finsterer, Josef, et al.
Publicado: (2022)

Musculoskeletal complications of COVID-19 can contribute to its morbidity and mortality
por: Finsterer, Josef, et al.
Publicado: (2022)

SARS-CoV-2 or SARS-CoV-2 vaccination associated Parsonage-Turner syndrome. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of spinal accessory nerve palsy” by Coll et al. Joint Bone Spine 2021;88:105196
por: Finsterer, Josef, et al.
Publicado: (2021)

Facial palsy 12 h after a first Moderna jab requires pathophysiological disclosure and verification of causality
por: Finsterer, Josef, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_20ho2onehushrs661i8ijs9or8